Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Artelo Biosciences ( (ARTL) ) just unveiled an update.
Artelo Biosciences executed a one-for-three reverse stock split of its common shares effective March 10, 2026, cutting its outstanding stock from 2,124,772 to about 708,323 shares and proportionally reducing authorized common and preferred share counts while leaving par value unchanged. In conjunction with the corporate action, the company republished its audited financial statements for 2024 and 2025, which were issued with a going-concern warning as the balance sheet shows mounting liabilities, shrinking cash, and a substantial accumulated deficit, underscoring ongoing financial pressure for shareholders and creditors.
The updated filings detail that total assets fell to $2.8 million against $4.1 million in liabilities at year-end 2025, resulting in negative stockholders’ equity. The independent auditor, which has served since 2015, affirmed the statements’ conformity with U.S. GAAP but flagged substantial doubt about Artelo’s ability to continue as a going concern, signaling elevated risk and potential future financing needs for the company and its stakeholders.
The most recent analyst rating on (ARTL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Spark’s Take on ARTL Stock
According to Spark, TipRanks’ AI Analyst, ARTL is a Neutral.
The score is primarily held down by weak financial performance (pre-revenue, sustained losses/cash burn, and negative equity). Technical indicators remain broadly bearish over longer timeframes, and valuation offers limited support given losses and no dividend. Corporate events add uncertainty due to Nasdaq compliance risk, only partially offset by new financing flexibility.
To see Spark’s full report on ARTL stock, click here.
More about Artelo Biosciences
Artelo Biosciences, Inc. is a Nevada-incorporated company operating in the biopharmaceutical sector, focused on developing cannabinoid- and lipid-based therapeutics. The company is listed in the U.S. public markets and targets investors in early-stage life sciences, but its latest audited accounts highlight recurring operating losses and a net capital deficiency that raise going-concern risks.
Average Trading Volume: 26,472
Technical Sentiment Signal: Sell
Current Market Cap: $2.94M
For an in-depth examination of ARTL stock, go to TipRanks’ Overview page.